Ferring Pharmaceuticals begins treatment of first US patient with ADSTILADRIN

Ferring Pharmaceuticals begins treatment of first US patient with ADSTILADRIN

Ferring Pharmaceuticals has announced that the first patient in the United States suffering from high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) has been administered with the intravesical gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg). The gene therapy was approved by the U.S. Food and Drug Administration (FDA) in December 2022 for the treatment of adult […]

Ferring bags Adstiladrin FDA approval in non-muscle invasive bladder cancer

Ferring bags Adstiladrin FDA approval in non-muscle invasive bladder cancer

Swiss biopharmaceutical company Ferring Pharmaceuticals has received approval for its Adstiladrin (nadofaragene firadenovec-vncg) gene therapy from the US Food and Drug Administration (FDA) for the treatment of a type of bladder cancer in adult patients. Adstiladrin, which is an adenovirus vector-based gene therapy, is indicated for treating high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) […]

Ferring Pharmaceuticals gets Rebyota FDA approval for recurring CDI

Ferring Pharmaceuticals gets Rebyota FDA approval for recurring CDI

Rebyota FDA approval : Ferring Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Rebyota (fecal microbiota, live-jslm), a microbiota-based live biotherapeutic, for the prevention of recurrence of Clostridioides difficile infection (CDI). Rebyota, a pre-packaged, single-dose 150 mL microbiota suspension for rectal administration, is indicated for use in individuals 18 years […]

Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy

Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy

Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to jointly invest more than $570 million in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy. Currently, nadofaragene firadenovec is in late-stage development for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). […]

Ferring Pharmaceuticals launches Nocdurna in US to treat nocturia

Ferring Pharmaceuticals launches Nocdurna in US to treat nocturia

Ferring Pharmaceuticals has announced the launch of Nocdurna (desmopressin acetate) in the United States, marking a significant advancement in the treatment of nocturia caused by nocturnal polyuria. This new medication is designed for adults who experience the disruptive need to urinate at least twice during the night. Nocdurna will be available by prescription in pharmacies […]